Samarbeid med eTheRNA kan kanskje nærme seg gjennombrudd? Kanskje med PCI Biotech?
Av samarbeidspartnere er eTheRNA den mest nærliggende? Noen som mener noe her?
Ny Twitter
@eTheRNA_immuno
has developed #mRNA formulation technologies tailored towards specific administration routes and optimized mRNA expression and biodistribution. Check out our Formulation Technologies factsheet to learn more: https://etherna.be/factsheets/ #biotech #mRNA
11:28 a.m. · 21. jun. 2021·Twitter Web App
«…boost intranodal administered naked antigen mRNA…»
…expected to enter a first in human study Q4 in 2021.
Er dette et hint på hva som KAN komme av mulig samarbeid?
Og det synes at markedet har glemt highlights fra Q1 2021:
Highlights
fimaCHEM
Increased screening and enrolment to RELEASE in Q1 after implementation of the amended protocol and the opening of Asian sites. The full effect of these initiatives is not expected until the Covid-19 situation improves further
The first US patient was enrolled in the RELEASE study in April
Continued focus on enrolment of patients into the RELEASE study, with the emphasis going forward being on regular trial management, including performance evaluation and replacement of underperforming sites
The expected timeline for the planned interim analysis remains in the range from 2H 2022 to 1H 2023
fimaVACC
Successful Phase I vaccination proof of concept study published in the high impact immunology journal, Frontiers in Immunology, demonstrating that fimaVACC enhances the immune response to peptide- and protein-based vaccines in healthy volunteers. The focus going forward is utilising the Phase I results in partnering efforts and planning for clinical proof-of-concept in a disease setting
fimaNAC
Encouraging data on enhanced delivery of mRNA for various medical applications was presented at the UK based 12th Annual RNA Therapeutics Virtual Conference in February 2021
In May 2021, PCI Biotech entered into an extensive research collaboration with the South Korean company OliX Pharmaceuticals, a leading developer of RNAi therapeutics
Og tekst i kvartalsrapport som sa noe meget interessant om RELEASE og mulighet for Asia partner:
Expansion of RELEASE to Asia
The expansion of RELEASE to Asia during second half of 2020 was done to enhance patient recruitment and provide access to hospitals and key opinion leaders in this region with higher prevalence of bile duct cancer, and the expansion may also open up the potential upside from a business perspective. The trial is open in South-Korea and Taiwan and other commercially interesting countries are considered to be Japan, Hong Kong and China. The Asian market is known to be fragmented and PCI Biotech do not foresee to commercialise fimaCHEM for bile duct cancer in Asia without a partner.
fimaVacc
As a next development step, PCI Biotech is actively exploring and preparing for a potential clinical proof-of-concept study for therapeutic vaccination in a relevant cancer disease.
The fimaVACC technology has potential to also enhance other vaccination technologies, such as mRNA.
The company is using international experts to assess the best possible development opportunities across vaccination technologies and diseases. The aim is to leverage the expected strengths of the fimaVACC technology, such as intratumoural and intradermal vaccine delivery, initially focusing on the most apposite cancer indication before a potential broadening of the deployment of this versatile platform.
Neste event for PCI Biotech:
- Nordic Biotech Summit, 29 June, virtual event hosted by LifeSci Advisors. Company presentation 15:30 CEST
Miraklenes tid er ikke over @FiloD som vi så med Danmark. Markedet tror ikke det vil skje noe positivt med PCIB ser det ut til. Tar markedet skammelig feil? Spennende sommer 
